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Background. Undifferentiated anaplastic carcinoma rarely develops from chronic hyperthyroidism. Although acute hyperthyroidism can develop prior to anaplastic transformation, chronic hyperthyroidism was thought to be a protective measure
against thyroid malignancy. Methods. A 79-year-old female presented acutely to the hospital with dyspnea. She had been taking
methimazole for chronic hyperthyroidism due to toxic thyroid nodules, previously biopsied as benign. Upon admission, imaging
showed tracheal compression, requiring a total thyroidectomy with tracheostomy for airway management. Results. Pathology
demonstrated undifferentiated anaplastic thyroid carcinoma. The patient passed away shortly after hospital discharge. Despite
treatment with methimazole for many years, abrupt enlargement of her toxic multinodular goiter was consistent with malignant
transformation. Chronic hyperthyroidism and toxic nodules are rarely associated with thyroid malignancy, with only one previous
report documenting association with anaplastic thyroid carcinoma. Conclusion. Progressive thyroid enlargement and acute
worsening of previously controlled hyperthyroidism should promote concern for disease regardless of baseline thyroid function.

1. Introduction
Historically, chronic hyperthyroidism had been considered
protective against thyroid carcinoma. Some data suggest
a lower incidence of papillary thyroid cancer in those
with lower TSH levels [1]. This presumably arises from a
decreased stimulatory effect on thyroid tissue presented by
the low serum thyroid stimulatory hormone (TSH) found in
hyperthyroidism. However, with the increasing incidence of
thyroid cancer seen over the past years, there appears to be
an improved understanding that thyroid carcinomas can also
arise in glands that are thyrotoxic due to Graves’ disease, toxic
multinodular goiter, and autonomously functioning thyroid
adenomas [2]. Recent review of the literature has shown the
risk of malignancy associated with toxic hot nodules ranges
from 1 to 10.3% [2] or even up to 15% in those with Graves’
disease [3]. Most of these documented malignancies are
differentiated thyroid carcinomas and very rarely medullary
thyroid cancer [4].
Anaplastic thyroid carcinoma (ATC) represents one
of the most aggressive endocrine tumors and constitutes

approximately between 1.6 and 5% of all thyroid malignancies
[5]. ATC comes with a dismal prognosis limited to a 10–20%
mean survival at 12 months [6]. Patients with ATC experience
significant local compressive symptoms due to a rapidly
evolving central neck mass (77%) along with dysphagia
(40%), hoarseness (40%), and stridor (24%) [7]. Metastases
are noted in 50% of patients at the time of diagnosis, most
commonly in the lungs (80%), bone (6–16%), and brain
(5–13%) [7]. Not uncommonly patients also develop thyrotoxicosis. Although thyrotoxicosis can develop in a gland
with ATC, it is rare to find ATC develop from underlying
longstanding hyperthyroidism. We found only one other
case in the literature of ATC arising from a patient with
chronic hyperthyroidism [8]. In this report, we present our
experience with a patient who developed ATC after many
years of hyperthyroidism and toxic multinodular goiter.

2. Patient
A 79-year-old Caucasian female presented to our institution
with chest pain, dyspnea, and a rapidly enlarging thyroid
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Figure 1: Significantly enlarged thyroid mass causing tracheal deviation to the right (blue arrow) with hypoattenuation within the left thyroid
lobe (red arrow) (a). Scattered calcifications (green arrows) apparent within the lesion (b) with extension into the anterior mediastinum and
continued deviation of the trachea (c).

goiter. The patient endorsed that she was previously quite
healthy aside from stable hyperthyroidism and a nonenlarging thyroid goiter. Her thyroid had been overactive for years,
treated with stable dose of 7.5 mg daily of methimazole for
at least the past four years. In 2002, 2003, and 2010, she had
had thyroid uptake scans indicating heterogeneous elevated
uptake consistent with toxic multinodular goiter and a cold
area was identified in the lower right lobe. In 2000 and
2010, she had biopsies of the nodules of the right and left
lobes with benign results. Since treatment with methimazole,
she had been asymptomatic up until three months prior to
presentation, living a mostly independent and having active
lifestyle that included cooking, gardening, and daily errands.
The patient’s family became concerned approximately
three months before presentation to our facility because
the patient lost a significant amount of weight while her
goiter rapidly enlarged. Soon after, she had sudden “terrible
pain” in the left side of her neck, diagnosed as an internal
jugular vein thrombus. At the time of this diagnosis, her
thyroid measured 8.4 × 12 cm. She saw her endocrinologist
who noted that her thyroid was hyperfunctioning again and
no longer controlled with her daily dose of methimazole,

which was subsequently increased. A month later, her labs
showed that her thyroid was even more overactive. Her dose
of methimazole was subsequently increased to 30 mg per
day. She was evaluated for surgery the following month, but
surgery was deferred due to uncontrolled hyperthyroidism.
The day prior to presentation at our institution she developed
chest pressure and tightness when lying down. A computed
tomography (CT) scan of her chest and neck showed that her
thyroid had grown to 9.8 × 13.2 cm.
Upon admission, her TSH measured <0.003 𝜇IU/L (reference range 0.5–4.70 𝜇IU/mL), free serum thyroxine (T4 )
measured 1.56 ng/dL (reference range 0.7–1.25 ng/dL), and
free serum triiodothyronine (T3 ) measured 2.4 pg/mL (reference range 1.7–3.7 pg/mL). Ultrasound of her thyroid showed
gross enlargement of both thyroid lobes with the largest
nodules measuring 9.7 cm in the left lobe and 5.1 cm in the
right lobe. Subsequent CT scan of her chest showed the
mass extending into the anterior mediastinum with scattered
calcifications within the mass (Figure 1). There was narrowing
of the trachea in addition to multiple pulmonary masses
throughout the visualized lung fields. She was continued
on methimazole (20 mg twice a day) while hospitalized
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Figure 2: (a) Intraoperative photograph of total thyroid specimen, greatest dimension 8.7 cm in size. (b) Microscopic pathology of squamoid
and undifferentiated thyroid cells.

(a)

(b)

Figure 3: Metastatic work-up demonstrates a pulmonary nodule within the right upper lobe (1.1 × 2.1 cm) with central cavitation (blue arrow)
(a) and increased 99 mTc HDP uptake within the right intratrochanteric femur positive for a destructive lytic lesion (red arrow) (b).

and started on propranolol and prednisone for symptomatic
control. Her free T4 improved and free T3 remained within
normal limits on this regimen.
Due to dyspnea and malignancy concerns, she underwent a total thyroidectomy two weeks after admission
to obtain a pathologic diagnosis. Intraoperative findings
included involvement of the left recurrent laryngeal nerve
and tracheal invasion. Intraoperative biopsies sent for frozen
section analysis were reported as poorly differentiated carcinoma, suggestive of anaplastic thyroid carcinoma (Figure 2).
As a result, a prophylactic tracheostomy was placed. The
final pathology report confirmed undifferentiated anaplastic
carcinoma (8.7 cm) involving the left thyroid, positive for
lymphatic involvement (2/5 central nodes) and extrathyroidal
extension to the pretracheal cartilage. Surgical margins were
positive along the left middle and inferior pole. The right
thyroid lobe had multiple benign nodes. Subsequent wholebody CT and nuclear medicine scan found multiple bilateral
pulmonary nodules with central cavitation and a destructive
right intertrochanteric lytic lesion with pathological fracture
(Figure 3). The final staging was pT4b N1b M1 anaplastic
thyroid carcinoma (American Joint Committee on Cancer
7th Edition). Chemotherapy was recommended for her ATC,

as she was deemed not a candidate for radiation therapy.
The patient’s family chose to pursue chemotherapy closer to
home. The patient quickly deteriorated towards the end of her
hospitalization and missed several follow-up appointments
with her medical oncologist upon discharge. She passed away
at home within a month after leaving the hospital.

3. Discussion
Chronic hyperthyroidism had long been thought to be
protective against the development of malignancy within
the thyroid gland [2]. Thus, development of thyroid cancer
within a hyperthyroid gland was thought to be uncommon.
However, meta-analyses have shown that thyroid cancer
can in fact develop in hyperthyroid glands, although it is
not common, and most of the malignancies identified in
hyperfunctioning thyroid glands have been differentiated
thyroid cancers. Conversely, acute thyroiditis can develop
in association with thyroid malignancies. For example, rare
cases of “malignant pseudothyroiditis” have been described
wherein local parathyroid malignancies or metastatic lesions
to the thyroid prompted thyroid inflammation and thyrotoxicosis [9]. ATC is also associated with acute thyrotoxicosis that
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develops around the time of acute malignant transformation
[2, 10]. A 2007 review of the association between ATC and
thyrotoxicosis outlines eight cases in the literature [10]. The
authors discuss the development of acute thyrotoxicosis with
anaplastic thyroid cancer as a consequence of rapid leakage
of thyroid hormone into the bloodstream from destroyed
thyrocytes. Phillips et al. argue that the acute hyperthyroid
state in ATC is caused by a hyperfunctioning metastatic
tumor [10]. Thyrotoxicosis associated with ATC has been
termed “anaplastic pseudothyroiditis” [11].
This situation, however, differs from our patient in that
thyrotoxicosis did not originate from the anaplastic tumor
but predated the malignant transformation by several years.
Our case shows the unique condition in which anaplastic
thyroid cancer developed from a hyperthyroid patient despite
several years of methimazole treatment. ATC is associated
with a previous history of thyroid goiter and is known to
be more common in geographic regions of endemic iodine
deficiency [7] but not associated with glands that have
previously been hyperfunctioning.
To our knowledge, a 2014 report by Marcelino et al. is the
only published case that associates chronic hyperthyroidism
with subsequent development of ATC [8]. Their study reports
a similar presentation in a 70-year-old male who had been
diagnosed with a toxic nodule three years prior to diagnosis of
ATC. He was conservatively managed with methimazole and
𝛽-adrenergic blockers. Three years later, he re-presented with
dyspnea, hoarseness, and dysphagia similar to our patient. A
subsequent neck CT scan showed a suspicious mass involving
the left thyroid lobe and isthmus (7 × 6 × 5 cm), with invasion
of the surrounding soft tissue, trachea, and recurrent nerve.
Their patient was not a surgical candidate and underwent
radiotherapy without much improvement in thyroid size
before passing away several weeks later of airway compression [8]. Similar to Marcelino et al., previous work-up of
our patient’s thyroid nodules, including biopsies of bilateral
nodules, was negative for malignancy. While her thyroid
uptake scans previously identified a cold nodule in the lower
right thyroid lobe, her surgical pathologic specimen of the left
thyroid lobe identified the anaplastic carcinomic tissue while
her right thyroid nodule was negative for anaplastic disease.
In addition, previous thyroid scans had elevated and patchy
uptake in the left lobe despite the pathologic finding. The
development of ATC from differentiated thyroid carcinoma
is well established [7], although our patient did not have this
diagnosis, based on the negative FNA years prior. Whether
our patient developed “de novo” ATC similar to what was
theorized by Marcelino et al. is debatable, but plausible
considering the fact that the previously toxic left thyroid
nodule was the one which developed ATC in our patient. This
was despite the presence of a cold nodule in the right thyroid
lobe which remained negative for malignancy after removal.
Undifferentiated anaplastic thyroid carcinoma is a rare
and underreported condition in the setting of chronic hyperthyroidism. There exists only one other reported case of this
association in the literature, also involving a septuagenarian
who developed rapid thyroid enlargement with tracheal
compression years after diagnosis and control of hyperthyroidism with methimazole. While current recommendations
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for treatment of hyperthyroidism involve medical therapy,
the presence of any nontoxic nodule in the thyroid, and
any toxic nodule with suspicious features, should warrant
work-up with ultrasound, fine needle aspirate, and ongoing
surveillance. Our case demonstrates that even those with
negative biopsy and longstanding hyperthyroidism are at risk
of development of anaplastic thyroid carcinoma.
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